scholarly journals Expression profiling of MMA-1a and splice variant MMA-1b: New cancer/testis antigens identified in human melanoma

2002 ◽  
Vol 98 (4) ◽  
pp. 547-553 ◽  
Author(s):  
Nicole J.W. de Wit ◽  
Ulrich H. Weidle ◽  
Dirk J. Ruiter ◽  
Goos N.P. van Muijen
Keyword(s):  
Expression Profiling ◽  
Splice Variant ◽  
Human Melanoma ◽  
Cancer Testis Antigens ◽  
Cancer Testis

scholarly journals Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status

2008 ◽  
Vol 215 (2) ◽  
pp. 287-291 ◽  
Author(s):  
Luca Sigalotti ◽  
Alessia Covre ◽  
Susan Zabierowski ◽  
Benjamin Himes ◽  
Francesca Colizzi ◽  
...  
Keyword(s):  
Stem Cells ◽  
Methylation Status ◽  
Human Melanoma ◽  
Cancer Testis Antigens ◽  
Cancer Testis

scholarly journals Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma

2009 ◽  
Vol 183 (2) ◽  
pp. 832-840 ◽  
Author(s):  
Maud Condomines ◽  
Dirk Hose ◽  
Thierry Rème ◽  
Guilhem Requirand ◽  
Michael Hundemer ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Myeloma ◽  
Gene Expression Profiling ◽  
Real Time ◽  
Real Time Pcr ◽  
Expression Profiling ◽  
Cancer Testis Antigens ◽  
Potential Cancer ◽  
Cancer Testis

scholarly journals Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2499
Author(s):  
Lisanne Noordam ◽  
Zhouhong Ge ◽  
Hadiye Özturk ◽  
Michail Doukas ◽  
Shanta Mancham ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Normal Liver ◽  
Occult Metastasis ◽  
Recurrence Rates ◽  
Curative Intent ◽  
Cancer Testis Antigens ◽  
Negative Prognostic Factor ◽  
Increased Risk ◽  
Hcc Recurrence ◽  
Cancer Testis

High recurrence rates after resection of hepatocellular carcinoma (HCC) with curative intent impair clinical outcomes of HCC. Cancer/testis antigens (CTAs) are suitable targets for cancer immunotherapy if selectively expressed in tumor cells. The aims were to identify CTAs that are frequently and selectively expressed in HCC-tumors, and to investigate whether CTAs could serve as biomarkers for occult metastasis. Tumor and paired tumor-free liver (TFL) tissues of HCC-patients and healthy tissues were assessed for mRNA expression of 49 CTAs by RT-qPCR and protein expression of five CTAs by immunohistochemistry. Twelve CTA-mRNAs were expressed in ≥10% of HCC-tumors and not in healthy tissues except testis. In tumors, mRNA and protein of ≥ 1 CTA was expressed in 78% and 71% of HCC-patients, respectively. In TFL, CTA mRNA and protein was found in 45% and 30% of HCC-patients, respectively. Interestingly, CTA-expression in TFL was an independent negative prognostic factor for post-resection HCC-recurrence and survival. We established a panel of 12 testis-restricted CTAs expressed in tumors of most HCC-patients. The increased risk of HCC-recurrence in patients with CTA expression in TFL, suggests that CTA-expressing (pre-)malignant cells may be a source of HCC-recurrence, reflecting the relevance of targeting these to prevent HCC-recurrence.

231 A novel discovery pipeline identifies melanoma-specific antibodies in patients responding to immune checkpoint inhibitors

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A249-A249
Author(s):  
Daniel Delitto ◽  
Evan Lipson ◽  
Laura Cappelli ◽  
Klaus Busam ◽  
Antony Rosen ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Treatment Response ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Tumor Regression ◽  
Checkpoint Inhibitors ◽  
Specific Antibodies ◽  
Cancer Testis Antigens ◽  
Circulating Antibodies ◽  
Cancer Testis

BackgroundTumor-specific antibodies have been reported in patients with cancers responding to immune checkpoint inhibitors (ICI), and there is an increasing appreciation for the potential role of B cells in mediating ICI responses. However, the humoral immune response to melanoma remains incompletely defined. We hypothesized that screening sera for antibodies by immunoprecipitation with lysates of cultured melanoma cells would increase the likelihood of detecting circulating antibodies in melanoma patients receiving ICI, and potentially identify novel antibody targets associated with treatment response and/or immune-related adverse events (IRAEs).MethodsPre-and on/post-treatment sera or plasma from 12 clinically-annotated patients with advanced metastatic melanoma receiving ICI were assayed for tumor-specific antibodies with an established immunoprecipitation platform. 35S-methionine-labeled lysates from cultured 624Mel cells were used for immunoprecipitation. 624Mel expresses several shared non-mutated melanoma antigens (e.g., MAGEA3, tyrosinase, MART-1/Melan-A, gp75, and gp100). Antigen identity was determined using on-bead digests followed by mass spectrometry, and was confirmed by immunoprecipitation with in vitro transcription/translation (IVTT) products.ResultsAntibodies reactive against 624Mel proteins were detected in 4 of 12 (33%) patients (table 1). Mass spectrometric sequencing performed on proteins captured with sera from 3 of 4 patients identified several putative antigens. Immunoprecipitation with IVTT candidate proteins confirmed antibodies against melanoma-associated and cancer testis antigens NY-ESO-1, SSX2 and MAGEA10. Antibodies were observed in 1 of 1 (100%) patient with a complete response, 2 of 4 (50%) with a partial response, 1 of 1 (100%) with stable disease, and 0 of 6 (0%) with progressive disease. Antibody levels varied over the course of therapy, with previously undetectable specificities arising during treatment response in patients #1–3. Patient #1 with a complete tumor regression developed antibodies to SSX2 and MAGEA10 that were absent before treatment. Further, detection of these antibodies coincided with diagnosis of IRAEs (anti-SSX2 with pancreatitis and anti-MAGEA10 with dermatitis). In contrast, patient #3, initially with a partial tumor regression, demonstrated a loss of detectable anti-NY-ESO-1 antibodies upon disease progression, and subsequent metastasectomy demonstrated loss of NY-ESO-1 protein expression in the progressing tumor. Testing sera from all 12 patients with IVTT products for NY-ESO-1, SSX2 and MAGEA10 did not reveal additional humoral responses.Abstract 231 Table 1Antibodies detected in the serum or plasma of patients with metastatic melanoma treated with ICI therapy. Treatment response indicates best overall response according to RECIST v1.1. Post-treatment blood collections were drawn during or after ICI therapy.ConclusionsOur comprehensive screening platform detected circulating antibodies specific to multiple melanoma-associated and cancer testis antigens in patients deriving clinical benefit from ICI. Expanded investigations of the evolution of antibody production over the course of ICI therapy, associated with tumor response to treatment and development of IRAEs, are warranted.AcknowledgementsThis study was supported by the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, and NIH P30-AR070254.Ethics ApprovalThis study was approved by the Johns Hopkins Institutional Review Board, approval #NA_00090257.

scholarly journals Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma

2012 ◽  
Vol 28 (5) ◽  
pp. 1792-1798 ◽  
Author(s):  
MYUNG-HA SONG ◽  
KYUNG-UN CHOI ◽  
DONG-HOON SHIN ◽  
CHANG-HUN LEE ◽  
SANG-YULL LEE
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cancer Testis Antigens ◽  
Cancer Testis

Targeting cancer-testis antigens in recurrent pediatric brain tumors

2015 ◽  
Vol 123 (1) ◽  
pp. 193-195
Author(s):  
Deepa K. Krishnadas ◽  
Fanqi Bai ◽  
Kenneth G. Lucas
Keyword(s):  
Brain Tumors ◽  
Pediatric Brain Tumors ◽  
Cancer Testis Antigens ◽  
Pediatric Brain ◽  
Cancer Testis
Sign in / Sign up

Export Citation Format

Share Document